In Phase C, members will acquire ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Members will obtain treatment until condition progression or even the individuals are unable to tolerate the study drugs. Possible new ways with the diagnosis and treatment of AML. (A) The identification https://abbv-744-and-other-brd4-i80134.bloggactif.com/33019089/helping-the-others-realize-the-advantages-of-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc